Don't Judge Masimo on Technicals Alone - Check Its Fundamentals!

By Blake Campbell • Tuesday, November 07 12:58 • Permanent Link

Masimo logged a -2.1% change during today's afternoon session, and is now trading at a price of $79.88 per share. The S&P 500 index moved 0.0%. MASI's trading volume is 453,510 compared to the stock's average volume of 972,778.

Masimo trades -38.85% away from its average analyst target price of $130.63 per share. The 8 analysts following the stock have set target prices ranging from $110.0 to $150.0, and on average have given Masimo a rating of buy.

Anyone interested in buying MASI should be aware of the facts below:

Masimo has moved -35.0% over the last year, and the S&P 500 logged a change of 15.0%
Based on its trailing earnings per share of 2.13, Masimo has a trailing 12 month Price to Earnings (P/E) ratio of 37.5 while the S&P 500 average is None
MASI has a forward P/E ratio of 20.5 based on its forward 12 month price to earnings (EPS) of $3.9 per share
The company has a price to earnings growth (PEG) ratio of 1.97 — a number near or below 1 signifying that Masimo is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 3.22 compared to its sector average of None
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide.
Based in Irvine, the company has 4,000 full time employees and a market cap of $4.22 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.